BM109 (Patented)

Isolated from our proprietary stool bank, YS Flora®

BM109 produces a series of enzymes that completely decompose TMAO, an independent risk factor for CVD and CKD

Arteriosclerosis, Myocardial infarction, Stroke, Cerebral infarction, Heart failure, Hemodialysis

The current medical landscape lacks effective interventions to reduce the blood levels of TMAO,
highlighting significant unmet needs in this area.

BM101 (Patented)

Isolated from the nasal cavity of a healthy individual

BM101 secretes a heat-resistant immune-stimulating molecule.

(i) Prevention of various respiratory viral infections,
(ii) Prevention of various hospital-acquired infections,
(iii) Vaccine sensitizer, (iv) immune-stimulating agent for cancer immunotherapy

BM101, in its heat-inactivated form known as parabiotics, is currently at preclinical stage.
The intranasal delivery of BM101 shows promise in providing protection against respiratory infections, particularly
for individuals at high risk of infection.

BM111, a consortium of fecal microbes (Patent in preparation)

Microbiome composition data of patients who exhibited response to FMT Isolated from our proprietary stool bank, YS Flora®

(i) Restoration of dysbiotic state, (ii) Physical decolonization of antibiotic-resistant pathogens

VRE, CPE infections

While antibiotic stewardship programs aim to support patients with infections, their effectiveness is limited, highlighting significant unmet needs in disease management.

BM105 (Patented)

A consortium of three fecal microbes, isolated from our proprietary stool bank, YS Flora®

BM105, upon transplantation into the host intestine, promotes the restoration of the dysbiotic state, which is a defining phenotype of IBD.

IBD

Current treatment options for IBD include the use of 5-ASA, steroids, and anti-TNF biologics.
However, there is a need for microbiome-based therapies to restore gut microbiome homeostasis.

BM107 (Patented)

Isolated from our proprietary stool bank, YS Flora®

BM107 (a food strain) + Tributyrin (three butyrate molecules bound to a glyceride backbone)

(i) Individuals with high-risk polyps for colorectal cancer, (ii) Irritable bowl syndrome (IBS)
(iii) Hyper-inflammatory conditions, (iv) Constipation

BM107, a potent synbiotic combination, generates butyrate within the intestine, precisely where its effectiveness is most desirable.